Insufficient data were available from randomized trials to establish if statins are safe and effective in cases of acute ischemic stroke and transient ischemic attack (TIA).
The authors searched the Cochrane Stroke Group's Trials Register (November 2010); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 4); MEDLINE (1950 to November 2010); and EMBASE (1980 to November 2010).
The authors included all randomized controlled trials (RCTs) comparing statins (any type and dosage) versus placebo or no treatment, administered within two weeks of the onset of acute ischemic stroke or TIA.
Two review authors independently selected studies for inclusion and extracted data.
The authors assessed methodological quality and, when necessary, contacted study authors for additional data.
The authors based quantitative analysis of outcome on the intention–to–treat principle.
The primary outcomes were mortality from ischemic stroke and mortality from adverse drug effects, bleedings and infections.
The authors estimated the overall treatment effect by the pooled odds ratio (OR) with 95% confidence interval (CI) using a fixed–effect model (Mantel–Haenszel).
The authors included eight RCTs involving 625 participants.
Only one study was judged as 'low risk' of bias.
There were insufficient published data from the eight studies for all planned primary and secondary outcomes.
No patients died from ischemic stroke or from adverse drug effects, bleeding or infections among the 444 participants in the six studies where these outcomes were reported.
Statin treatment did not reduce all–cause mortality compared with placebo or no treatment (OR 1.51, 95% CI 0.60 to 3.81) in the 431 patients enrolled in seven studies.
No cases of rhabdomyolysis (the breakdown of muscle fibres resulting in the release of muscle fibre contents (myoglobin) into the bloodstream) occurred in 274 patients enrolled in three studies.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.